<DOC>
	<DOCNO>NCT01073059</DOCNO>
	<brief_summary>- This trial conduct assess pharmacokinetic characteristic valproic acid valproic acid single treatment valproic acid &amp; ertapenem combination treatment - This trial perform evaluate safety combination treatment compare single treatment - The investigator carry trial study mechanism combination treatment</brief_summary>
	<brief_title>Pharmacokinetic Interactions Combination Treatment Valproic Acid Ertapenem Normal Subjects</brief_title>
	<detailed_description />
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Subjects healthy volunteer , men 19~50 year Subjects weight 50kg condition ± 20 % range ideal weight Subjects evidence clinically significant hepatic , pancreatic , renal , neurological , pulmonary , endocrine , blood tumor , psychiatric cardiovascular disease Subjects GI disease ( crohn 's disease , etc . ) would increase influence absorbance medication GI surgery exclude appendectomy hernia surgery Subjects uncontrolled hypotension ( indicated sit systolic blood pressure≤ 100 mmHg diastolic blood pressure≤ 65 mmHg measure ) hypertension ( indicated sit systolic blood pressure≥ 150 mmHg diastolic blood pressure≥ 95 mmHg measure ) vital sign measurement Subjects know allergy , hypersensitivity ( anaphylaxistype reaction ; especially penicillin antibiotic ) Subjects history drug abuse Subjects receive certain medication ( include oriental medicine ) within past 3 week certain OTCdrug within 1 week Subjects participate clinical investigation within 2months prior first administration Subjects whole blood donation ( within 2months ) apheresis ( within 1months ) prior first administration Subjects chronic drinker</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>valproic acid</keyword>
	<keyword>ertapenem</keyword>
</DOC>